Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
4D Molecular Therapeutics, Inc. - Common Stock (FDMT) Institutional Ownership
CUSIP: 35104E100
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
149
Shares (Excl. Options)
53,383,257
Price
$7.50
Save this security research path
Keep this CUSIP in your research flow, then return after the next filing cycle to check what changed.
- Type / Class
- Equity / Common Stock
- Symbol
- FDMT on Nasdaq
- Shares outstanding
- 50,943,214
- Price per share
- $9.31
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 53,383,257
- Total reported value
- $400,363,706
- % of total 13F portfolios
- 0%
- Share change
- +13,991,310
- Value change
- +$104,755,232
- Number of holders
- 149
- Price from insider filings
- $9.31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FDMT - 4D Molecular Therapeutics, Inc. - Common Stock is tracked under CUSIP 35104E100.
- 149 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 149 to 6 between Q4 2025 and Q1 2026.
- Reported value moved from $400,363,706 to $1,380,334.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 35104E100?
CUSIP 35104E100 identifies FDMT - 4D Molecular Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 35104E100:
Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $45,959,629 | +$9,546,222 | 5,847,281 | +26% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $44,910,877 | +$9,031,022 | 5,713,852 | +25% | RA Capital Management, L.P. | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC | 10% | +28% | $48,852,550 | +$5,691,163 | 5,247,151 | +13% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| GOLDMAN SACHS GROUP INC | 7.5% | -21% | $33,688,569 | -$1,079,634 | 4,286,077 | -3.1% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
| Novo Holdings A/S | 6.4% | -5.7% | $28,694,793 | +$3,739,293 | 3,650,737 | +15% | Novo Holdings A/S | 31 Dec 2025 |
| BlackRock, Inc. | 6.6% | -15% | $26,613,959 | -$4,803,137 | 3,062,596 | -15% | BlackRock, Inc. | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 1.5% | -82% | $2,202,200 | -$7,393,006 | 677,600 | -77% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| Deep Track Capital, LP | 1.3% | $1,982,175 | 609,900 | Deep Track Capital, LP | 31 Dec 2024 |
As of 31 Dec 2025, 149 institutional investors reported holding 53,383,257 shares of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT). This represents 105% of the company’s total 50,943,214 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) together control 92% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 5,653,211 | +24% | 0.44% | $42,399,083 |
| JANUS HENDERSON GROUP PLC | 9.1% | 4,635,875 | +164% | 0.02% | $34,726,165 |
| BVF INC/IL | 9.1% | 4,629,289 | 0% | 1.2% | $34,719,668 |
| GOLDMAN SACHS GROUP INC | 8.4% | 4,302,905 | +4.2% | 0% | $32,271,789 |
| BlackRock, Inc. | 8% | 4,064,876 | +5.1% | 0% | $30,486,573 |
| NOVO HOLDINGS A/S | 7.2% | 3,650,737 | +83% | 2.1% | $27,380,528 |
| VANGUARD GROUP INC | 6.1% | 3,093,527 | +20% | 0% | $23,201,453 |
| STATE STREET CORP | 5.3% | 2,688,880 | +198% | 0% | $20,166,600 |
| ARMISTICE CAPITAL, LLC | 3.8% | 1,936,000 | +77% | 0.36% | $14,520,000 |
| FEDERATED HERMES, INC. | 3.2% | 1,609,482 | +0.92% | 0.02% | $12,071,116 |
| Point72 Asset Management, L.P. | 3% | 1,539,860 | 0.02% | $11,548,950 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.4% | 1,235,156 | +606% | 0.01% | $9,263,670 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,012,025 | +11% | 0% | $7,591,665 |
| Evergreen Quality Fund GP, Ltd. | 1.9% | 951,474 | 0.14% | $7,136,055 | |
| BANK OF AMERICA CORP /DE/ | 1.6% | 832,591 | +1.6% | 0% | $6,244,433 |
| DEUTSCHE BANK AG\ | 1.4% | 704,207 | +30% | 0% | $5,281,553 |
| MORGAN STANLEY | 1.3% | 672,695 | -20% | 0% | $5,045,215 |
| RENAISSANCE TECHNOLOGIES LLC | 1% | 512,900 | +64% | 0.01% | $3,846,750 |
| Parkman Healthcare Partners LLC | 0.99% | 503,431 | +152% | 0.36% | $3,775,733 |
| ArrowMark Colorado Holdings LLC | 0.95% | 485,389 | -3.7% | 0.08% | $3,640,418 |
| RAYMOND JAMES FINANCIAL INC | 0.94% | 477,505 | +1.3% | 0% | $3,581,288 |
| RTW INVESTMENTS, LP | 0.93% | 475,737 | 0.04% | $3,568,028 | |
| BAKER BROS. ADVISORS LP | 0.93% | 475,737 | 0.02% | $3,568,028 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.69% | 353,391 | +16% | 0% | $2,650,433 |
| TWO SIGMA INVESTMENTS, LP | 0.66% | 337,503 | +23% | 0% | $2,531,273 |
Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 148,256 | $1,380,334 | -$8,729 | $9.31 | 6 |
| 2025 Q4 | 53,383,257 | $400,363,706 | +$104,755,232 | $7.50 | 149 |
| 2025 Q3 | 39,480,388 | $343,063,699 | -$4,201,365 | $8.69 | 129 |
| 2025 Q2 | 40,369,426 | $149,859,289 | -$9,235,482 | $3.71 | 117 |
| 2025 Q1 | 43,058,381 | $139,823,044 | -$22,403,324 | $3.23 | 122 |
| 2024 Q4 | 46,814,824 | $260,642,119 | -$79,332,651 | $5.57 | 140 |
| 2024 Q3 | 57,948,767 | $626,374,639 | -$34,446,524 | $10.81 | 135 |
| 2024 Q2 | 57,307,189 | $1,203,018,791 | +$3,520,347 | $20.99 | 138 |
| 2024 Q1 | 56,228,706 | $1,790,823,856 | +$449,592,828 | $31.86 | 146 |
| 2023 Q4 | 42,433,937 | $859,819,319 | +$24,792,782 | $20.26 | 111 |
| 2023 Q3 | 41,913,779 | $533,559,212 | +$5,221,810 | $12.73 | 110 |
| 2023 Q2 | 41,248,927 | $745,334,512 | +$197,052,931 | $18.07 | 100 |
| 2023 Q1 | 30,404,028 | $522,337,328 | +$34,968,755 | $17.19 | 94 |
| 2022 Q4 | 28,011,571 | $622,110,124 | +$47,681,640 | $22.21 | 97 |
| 2022 Q3 | 26,181,987 | $210,496,945 | +$1,974,268 | $8.04 | 84 |
| 2022 Q2 | 26,027,061 | $181,670,139 | -$2,172,042 | $6.98 | 86 |
| 2022 Q1 | 26,134,053 | $395,189,957 | +$20,420,485 | $15.12 | 76 |
| 2021 Q4 | 24,702,968 | $541,790,297 | +$81,054,878 | $21.94 | 77 |
| 2021 Q3 | 18,711,908 | $504,667,012 | +$57,523,278 | $26.97 | 61 |
| 2021 Q2 | 16,612,608 | $400,026,000 | +$731,531 | $24.08 | 54 |
| 2021 Q1 | 15,384,514 | $664,816,567 | +$34,097,345 | $43.38 | 63 |
| 2020 Q4 | 14,593,004 | $602,432,000 | +$578,482,000 | $41.45 | 51 |